Study guide

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays

Key Takeaways Explain This Topic AI

ICH S2(R1) accepts two equivalent batteries: Option 1 is Ames plus one in vitro mammalian assay (MLA, chromosomal aberrations, or in vitro micronucleus) plus in vivo hematopoietic micronuclei; Option 2 is Ames plus two in vivo tissues, usually marrow micronuclei and liver comet.

OECD 471 Ames tester set is TA98, TA100, TA1535, TA1537 (or TA97/TA97a), and TA102 or E. coli WP2 uvrA or WP2 uvrA(pKM101), each run with and without induced rat-liver S9.

Plate incorporation mixes bacteria, test article, and ±S9 in overlay agar; preincubation holds that mix in liquid first and better detects short-lived metabolites, many azo compounds, and some volatiles.

A micronucleus is a membrane-bounded cytoplasmic chromatin body containing either an acentric chromosomal fragment (clastogen) or a whole lagging chromosome (aneugen); OECD 487 is in vitro and OECD 474 is in vivo erythrocyte micronuclei.

A positive in vitro mammalian assay with a negative in vivo micronucleus is not closed unless two adequate in vivo tissues show exposure; a negative marrow test without proof of exposure is uninformative.

Last updated: September 2026

Why genetic toxicology is scored as interpretation

Handbook Domain I.C asks you to interpret specialized endpoints, not merely recite a guideline number. Genetic toxicology assays ask whether an agent can change DNA sequence or break or mis-segregate chromosomes in a way that could matter for somatic cancer risk or, less often, germ-cell risk. ExamFinch independent study material for this section covers the International Council for Harmonisation (ICH) S2(R1) battery and the Organisation for Economic Co-operation and Development (OECD) methods laboratories actually run. It is not an ABT product and does not claim official approval, review, or partnership with ABT, ICH, or OECD.

A mutagen changes DNA sequence. A clastogen breaks chromosomes. An aneugen causes whole-chromosome loss or gain by interfering with the spindle. No single plate or slide sees all three. That is why S2(R1) is a battery.

Two equally acceptable ICH S2(R1) options

S2(R1) applies to pharmaceuticals intended for human use. Two options are treated as equivalent.

Option 1 (more historical experience): (i) a bacterial reverse-mutation test (Ames; OECD 471 ); (ii) an in vitro mammalian test for chromosomal damage or mutation—metaphase chromosomal aberrations , the mouse lymphoma L5178Y Tk assay (MLA) , or the in vitro micronucleus assay (OECD 487) ; and (iii) an in vivo test for chromosomal damage in rodent hematopoietic cells, usually the micronucleus assay (OECD 474) .

Option 2: (i) Ames; and (ii) in vivo assessment in two tissues , usually hematopoietic micronuclei plus a second assay, typically a DNA strand-break ( comet ) assay in liver unless another tissue is justified by distribution or first-pass biology.

The options are equivalent because of follow-up logic. When an in vitro mammalian assay is positive, clearly negative results in two well-conducted in vivo assays, in appropriate tissues, with demonstrated adequate exposure , are considered sufficient evidence that genotoxic potential is not expressed in vivo. Option 2 simply runs that two-tissue package up front. Either acute or repeat-dose in vivo designs may be used; when a repeat-dose toxicology study already exists, integrate micronucleus or comet endpoints rather than adding a standalone animal experiment.

Ames test (OECD 471): what the bacteria report

The Ames assay uses histidine-requiring Salmonella typhimurium (or tryptophan-requiring Escherichia coli ) that cannot form colonies on minimal medium unless a reverse mutation restores prototrophy. Counted colonies are revertants , not toxicity survivors. You still inspect the background lawn : thinning or clearing means cytotoxicity, which can suppress revertants and, if the lawn collapses, create scoring artifacts.

The recommended set detects both frameshift and base-substitution events:

TA98: frameshift ( hisD3052 ), rfa deep-rough lipopolysaccharide (increases permeability), uvrB excision-repair deficiency, plasmid pKM101 (error-prone SOS).

TA100: base-pair substitution ( hisG46 ) plus rfa, uvrB, and pKM101.

TA1535: the same hisG46 allele as TA100 but without pKM101 , so some alkylators that look modest in TA100 are clearer here.

TA1537 (or TA97 / TA97a ): frameshift at a different locus ( hisC3076 for TA1537).

TA102 or E. coli WP2 uvrA or WP2 uvrA (pKM101): AT-rich targets that catch oxidative mutagens, some cross-linkers, and agents missed by GC-centered Salmonella his alleles. TA102 carries hisG428 on plasmid pAQ1 and retains uvrB function.

A complete Ames for S2/OECD purposes is this five-strain set (the last slot filled by TA102 or a WP2 variant), not a two-strain screen.

Metabolic activation and the two mixing methods

Bacteria lack mammalian cytochrome P450. Each strain is therefore tested with and without an exogenous activation system, usually Aroclor 1254- or phenobarbital/β-naphthoflavone-induced rat-liver S9 (the post-mitochondrial supernatant) plus an NADPH-generating mix. Direct-acting mutagens (sodium azide, 9-aminoacridine, many nitroarenes) appear without S9. Promutagens (2-aminoanthracene, benzo[a]pyrene, many aromatic amines) appear only with S9. An isolated +S9 response is not a failed assay; it is evidence of bioactivation .

Plate incorporation mixes bacteria, test article, and ±S9 into soft agar and pours the overlay. Preincubation holds bacteria, test article, and ±S9 in liquid for a short period (often 20–30 minutes) before plating. Preincubation improves detection of short-lived metabolites, many azo compounds, and some volatiles. For pharmaceuticals, S2(R1) accepts either method for a single adequate experiment if the result is clearly negative or clearly positive; weak or equivocal results may need a repeat with tighter doses or a switch of method. Top dose is generally 5000 µg/plate (or 5 µL/plate) unless solubility or cytotoxicity forces a lower top. Positive and vehicle controls are required for every strain and activation condition.

In vitro mammalian assays: MLA and chromosomal aberrations

The MLA scores mutation at the heterozygous Tk locus. Large colonies tend to reflect gene mutation; small colonies tend to reflect chromosomal events that also delete Tk. A global evaluation factor is used in interpretation. Metaphase chromosomal aberration assays ( OECD 473 ) score gaps, breaks, and exchanges in cultured cells. For pharmaceuticals, S2(R1) generally caps the top concentration at 1 mM or 0.5 mg/mL , whichever is lower, unless solubility or cytotoxicity bites first. Both assays are typically run ±S9. Mammalian in vitro tests are more sensitive than Ames to some clastogens and to cytotoxicity-driven artifacts. A lone in vitro positive does not equal a human mutagen.

Micronuclei: fragments versus whole chromosomes

A micronucleus is a small, membrane-bounded chromatin body in the cytoplasm, separate from the main nucleus. It forms at anaphase when a chromosome fragment or an entire chromosome fails to join a daughter nucleus. Clastogens produce acentric fragments (no kinetochore). Aneugens produce lagging whole chromosomes (kinetochore/centromere-positive by CREST or FISH). Size and centromere staining distinguish mechanism; a raw micronucleus count does not.

OECD 474 is the in vivo mammalian erythrocyte micronucleus test (bone-marrow polychromatic erythrocytes (PCE) or peripheral-blood reticulocytes). OECD 487 is the in vitro mammalian cell micronucleus test, often with cytochalasin B so you score binucleate cells that completed one mitosis. In vivo, you must show the marrow was exposed: a drop in the PCE/NCE (or reticulocyte) ratio, toxicokinetic data, or both. A “negative” in vivo micronucleus without evidence of exposure is uninformative, not reassuring.

Follow-up when in vitro is positive and in vivo is negative

If Ames is negative but the in vitro mammalian assay is positive, do not stop at a single negative bone-marrow micronucleus unless a well-supported non-DNA mechanism (extreme cytotoxicity, pH, osmolarity, or precipitate) already explains the in vitro result. S2(R1) expects two adequate in vivo assays in different tissues with demonstrated exposure —classically hematopoietic micronuclei plus liver comet ( OECD 489 )—before concluding that genotoxic potential is not expressed in vivo. If Ames itself is clearly positive, the molecule is a bacterial mutagen until chemistry, impurity, or metabolic arguments convincingly remove human relevance; in vivo negatives do not automatically erase a robust Ames positive.

Assay Detects Metabolic activation Typical use

Ames (OECD 471) Gene mutation (base substitution and frameshift) in bacteria ± induced rat-liver S9 S2 Option 1 and Option 2; chemical mutagenicity

In vitro chromosomal aberrations (OECD 473) Structural chromosome damage in cultured metaphases ±S9 S2 Option 1 mammalian in vitro

MLA (Tk) Gene mutation and chromosomal damage (colony size) ±S9 Alternative to chrom abs in Option 1

In vitro micronucleus (OECD 487) Micronuclei (clastogen or aneugen) in cultured cells ±S9 Alternative mammalian in vitro

In vivo micronucleus (OECD 474) Micronuclei in PCE or reticulocytes Whole-animal metabolism Option 1 in vivo; Option 2 first tissue

In vivo comet (OECD 489) DNA strand breaks, often liver Whole-animal metabolism Option 2 second tissue; follow-up of in vitro positives

Realistic scenario

A small-molecule investigational new drug (IND) package shows a clear Ames negative across the five-strain set ±S9, a positive in vitro micronucleus only at precipitating, highly cytotoxic concentrations, and a negative OECD 474 with a documented PCE-ratio decrease and plasma exposure above the clinical Cmax. The next scientific question is not “the in vitro test failed.” It is whether a second in vivo tissue (liver comet) is still needed. If the in vitro signal is confined to precipitating cytotoxic concentrations and marrow exposure is proven, S2(R1) still wants a documented weight-of-evidence write-up; many reviewers still want the second tissue unless the artifact case is airtight.

Traps

Treating TA98 plus TA100 as a complete Ames.

Calling a −S9-only positive “incomplete” when +S9 plates were run and negative—that pattern is bioactivation biology, not a missing condition, if both arms were actually tested.

Equating plate incorporation with preincubation for short-lived metabolites.

Treating micronuclei as DNA adducts rather than membrane-bounded chromosomal fragments or whole chromosomes.

Declaring in vivo safety from a micronucleus study that never proved marrow exposure.